Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Astellas Pharma : Announces Key Leadership Promotions in Human Resources, Legal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2019 | 09:47am EST

NORTHBROOK - Astellas today announced the promotions of Catherine Levitt to senior vice president, commercial, regulatory, medical & development and Rx+/transactional reporting to Linda Friedman, executive vice president and Astellas general counsel and Charlotte Stanton to vice president, human resources, rewards reporting to Fumiaki Sakurai, chief administrative officer and chief ethics & compliance officer.

Levitt will lead a new commercial, regulatory, medical & development and Rx+/transactional (CRMDT) organization that will serve as a global strategic legal partner to the chief commercial officer, chief strategy officer and chief medical officer.

'I am very excited about this new structure as it represents the next phase in our evolution as a global legal function and the continued growth of our culture of excellence,' said Friedman. 'Our new structure will allow us to have the tools and agility to further enhance development opportunities for our team as well as drive global consistency, maximize efficiencies and continue to provide best-in-class legal support to all of our clients globally.'

Levitt joined Fujisawa in 2004 as assistant general counsel, specializing in litigation. After the formation of Astellas in 2005, she was promoted to associate general counsel, followed by deputy general counsel. In 2013, she was promoted to vice president, risk management and chief litigation counsel; followed by vice president of US legal in April 2016, and vice president, regional general counsel and secretary of Astellas Americas in April 2017. Prior to Astellas, she served as corporate counsel at Baxter Healthcare and People's Energy, and began her career at the law firm of McDermott Will & Emery LLP. Levitt earned her JD from the University of Illinois College of Law.

Stanton will have global responsibility for the reward function within HR and serve as a member of the core HR leadership team. In this role, Stanton will lead the design and implementation of competitive, performance-driven and fair reward programs inclusive of compensation, benefits, and global mobility aligned to Astellas' business and people strategies and collaborate with HR business partners to support the business as one unified team.

'The globalization of our HR structure will enable us to further leverage and facilitate operational efficiencies, while also focusing more directly on quality in core processes,' said Sakurai. 'I believe that this investment within the HR organization will deliver a new level of excellence for our colleagues worldwide.'

Stanton joined Astellas in 2011 as head of Americas compensation, benefits, HRIS and payroll. In 2015, she was promoted to also lead Americas talent acquisition and in 2017 she became the global HR release lead for the Employee Central/HR Connect initiative. Prior to Astellas, she served as a compensation co-sourcing business leader at Hewitt Associates and vice president of compensation with ACNielsen. She began her career at the Hay Group as a consultant. Stanton earned a BS and MBA from Vanderbilt University.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Contact:

Stacy Harris

Tel: 224-205-8117

Email: stacy.harris@astellas.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC.
01/23ASTELLAS PHARMA : Amgen astellas biopharma to become a wholly owned amgen affili..
PU
01/17ASTELLAS PHARMA : Announces Construction of New Manufacturing Facility for Activ..
AQ
01/14Amgen CEO expects 25% of growth to come from Asia in next decade
RE
01/09ASTELLAS PHARMA INC. : - U.S. FDA Approves Supplemental New Drug Application for..
AQ
01/05ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
PU
2019ASTELLAS PHARMA : Strengthens Immuno-oncology Pipeline with Acquisition of Xypho..
AQ
2019Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
RE
2019ASTELLAS PHARMA : Strengthens Immuno-oncology Pipeline with Acquisition of Xypho..
PU
2019Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing dea..
RE
2019Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing dea..
RE
More news
Financials (JPY)
Sales 2020 1 266 B
EBIT 2020 256 B
Net income 2020 203 B
Finance 2020 497 B
Yield 2020 2,13%
P/E ratio 2020 17,5x
P/E ratio 2021 17,0x
EV / Sales2020 2,44x
EV / Sales2021 2,35x
Capitalization 3 589 B
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 2 079,17  JPY
Last Close Price 1 916,50  JPY
Spread / Highest target 46,1%
Spread / Average Target 8,49%
Spread / Lowest Target -21,7%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Senior Executive Officer & Head-Finance
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.3.51%32 809
JOHNSON & JOHNSON1.68%390 359
ROCHE HOLDING AG4.27%284 454
PFIZER1.63%220 369
MERCK AND COMPANY-5.46%218 904
NOVARTIS-0.09%213 484